Drug intelligence / Profile preview

multivirus-specific cytotoxic T lymphocytes (The First Affiliated Hospital of USTC)

Development stage
Unknown
Lead developer
Baylor College of Medicine
Modality
Cell Therapies
Administration
Intravenous
01

Overview

Multivirus-specific cytotoxic T lymphocytes (mVSTs) are an autologous cell therapy consisting of T cells expanded ex vivo to target multiple viral pathogens simultaneously. In the context of the clinical study by Anhui Provincial Hospital (ChiCTR2200060163), these cells are expanded using specific cytokine culture systems to treat or prevent infections from cytomegalovirus (CMV), Epstein-Barr virus (EBV), and adenovirus (ADV) in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation. The therapy works by restoring the host's cellular immunity against these opportunistic viruses, which can cause significant morbidity and mortality in the absence of a robust T-cell response. The expansion process is designed to produce a polyclonal population of T cells capable of recognizing viral antigens presented on MHC molecules, leading to the targeted destruction of infected cells.

Other names
multivirus-specific T cellsmultivirus-specific CTLsautologous multivirus-specific cytotoxic T lymphocytes
02

Targets

Epstein-Barr virus antigens presented as peptide-HLA complexesCytomegalovirus antigens presented as peptide-HLA complexespMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on multivirus-specific cytotoxic T lymphocytes (The First Affiliated Hospital of USTC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on multivirus-specific cytotoxic T lymphocytes (The First Affiliated Hospital of USTC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call